Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 6/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608929 | 0.81 | HTR6 (0.49) | HTR6PIK3CAATRATRIP | |
| SCHEMBL3612958 | 0.79 | PIK3CA (0.45) | PIK3CAPIK3R1ATRATRIP | |
| SCHEMBL3602620 | 0.79 | AKT1 (0.44) | HTR6RAF1BRAFATRATRIP | |
| SCHEMBL14042660 | 0.64 | ATR (0.42) | PIK3CAATRALDH1A1LMNA | |
| SCHEMBL16990360 | 0.61 | TDO2 (0.52) | HTR6PIK3CAALDH1A1 | |
| SCHEMBL28313371 | 0.61 | HTR6 (0.59) | HTR6 | |
| SCHEMBL15757698 | 0.60 | HTR6 (0.54) | HTR6ALDH1A1LMNA | |
| SCHEMBL3620801 | 0.60 | HTR6 (0.66) | HTR6ALDH1A1LMNA | |
| SCHEMBL16796479 | 0.59 | HTR6 (0.75) | HTR6 | |
| SCHEMBL2432960 | 0.59 | HTR6 (0.64) | HTR6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | HTR6 1760/4885PIK3CA 1/4885PIK3R1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.